Targeting NAD + metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression.
Qingcan SunMengying ShenSubin ZhuYanxia LiaoDongyan ZhangJingyuan SunZeqin GuoLeyuan WuLushan XiaoLi LiuPublished in: Hepatology international (2023)
levels or high TET2 levels.
Keyphrases